NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jan 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
9
Data completeness
7/8 — Comprehensive
KAPSPARGO SPRINKLE (metoprolol succinate) by Teva is 1 -selective (cardioselective) adrenergic receptor blocking agent. Approved for hypertension, heart failure. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAPSPARGO SPRINKLE is an extended-release oral capsule formulation of metoprolol succinate, a beta-1 selective adrenergic receptor blocking agent approved in 2018. It treats hypertension, heart failure, angina pectoris, and related cardiovascular conditions by reducing cardiac output and oxygen demand. The drug works through competitive antagonism of catecholamines at cardiac adrenergic sites and suppression of renin activity.
$2MPart D
Peak9.2 years to LOEModest Part D spending and claims volume in peak lifecycle phase suggest stable but limited brand-focused growth; smaller team infrastructure likely compared to blockbuster competitors.
Mechanism of Action
1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic…
Indications (2)
Worked on KAPSPARGO SPRINKLE at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.